IDDM is a chronic inflammatory disease in which there is autoimmune-mediated organ-specific dtstmction of the insulin-producing p-cells in the pancreatic islets of Langerhans. 'lhe migration of autoreactive lymphocytes and other leukocytes from the bloodstream into the target organ is of clear importance in the etiology of many organ-specific autoimmunelinflanunatoqy disorders, including IllDM. In IDDM, this migration results in lymphocytic invasion of the islets (formation of insulitis) and subsequent destruction of p-cells. Migration of lymphocytes from the bloodstream into tissues is a complex process involving sequential adhesioe and activation events. This migration is controlled in part by selective expression and functional regulation of cell adhesion molecules (CAMs) on the surface of lymphocytes and vascular endothelial cells or in the extracellular matrix. Understanding the mechanisms that regalate lymphocyte migration to the pancreatic islets will lead to further understanding of the pathogenesis of IaDM. In this article, we summaxize the recent advances regarding the function of CAMs in the development of IDDM in animal models and in humans and discuss the potential for developing CAM-based therapies for IDDM. Diabetes 45: 705-710, 1996 M ost lymphocytes recirculate throughout the body, migrating from blood through organized lymphoid tissues such as lymph nodes (LNs) and Peyer's patches (PPs) or extranodal tissues such as the pancreas, then to lymph and back to blood. This migration is important in establishing effective immune surveillance ill that it allows effector lymphocytes to migrate to almost any site of antigen deposition. However, the migra-tion can also cause localized chronic inflammation that leads to damage and destruction of host tissue. IDDM is one example of such a tissue-specific chronic inflammatory disorder (1) (2) (3) .
Lymphocyte migration from blood into tissue is a highly complex process involving a cascade of adhesion and activation events (4-7). As illustrated in Fig. 1 , many of the adhesion events involve interaction of lymphocyte cell adhesion molecules (CAMs) with their endothelial cell (EC) ligands. Some CAMs, such as lymphocyte function-associated antigen-1 (LFA-1) and EC vascular cell adhesion molecule-1 (VCAM-I), seem to be involved in lynlphocyte migration to a wide variety of tissues (8, 9) . In contrast, other CAMs are involved in lymphocyte migration to one or a few tissues. The lymphocyte CAMs associated with tissue-selective migration are known as homing receptors (10-13); their endothelial ligands, expressed in a tissue-selective manner either constitutively in uninflamed tissues or induced in inflamed tissues, are called vascular addressins (14) (15) (16) . CELL ADHESION MOLECULES: NOMENCLATURE, STRUCTURE, AND FUNCTION CAMS can be classified into at least three major groups based on their molecular structure: selectins, integrins, and the immunoglobulin (Ig) superfamily (17) . We will focus on lymphocyte and EC CAMs that appear to be involved in the pathogenesis of IDDM (Table 1) . Several excellent reviews are available that give more detailed information on the other leukocyte and EC CAMs (9, 17, 18) . L-selectinRNAd. L-selectin is a member of the selectin family of CAMs characterized by an NH,-terminal carbohydrate-binding lectin domain that binds to carbohydrate determinants on several EC glycoproteins (10, 19) . These glycoproteins are collectively known as peripheral node addressin (PNAd), many of which react with monoclonal antibody (mAb) MECA-79 (Table 1) (14) . L-selectin is expressed on most mononuclear cells except for some activated andlor menlory lymphocytes and functions to mediate an initial and transient attachment, or rolling, of leukocytes on vascular ECs (9, 17, 20) . L-selectin is involved in lymphocyte traficking to some extranodal sites of inflammation, including the thymus, skin, and pancreas (21) (22) (23) (24) (25) (26) (11, 12, 28) . MAdCAM-1, a glycoprotein with several Ig-like domains and a single mucin domain, is constitutively expressed by vessels in mucosal lymphoid organs (PPs and mesenteric LNs), intestinal lamina propria, and exocrine pancreas (15, 19, 25) . a4P7 also binds to VCAM-1 and fibronectin, both of which are ligands for a4pl integrin (30) . aLP2 integrin/ICAMs. The P2-integrin (CD18) can pair with various cw-chain integrins (CD11) to form functionally distinct CAMs. For instance, P2 pairing with aL forms cwLP2, known as LFA-1 (CDlla/CD18), which is expressed on all leukocytes, while Mac-1 (CDllbICDlS), formed by pairing of P2 with cwM, is predominantly expressed by macrophages and neutrophils (Table 1 ). Lymphocyte LFA-1 is thought to participate in the binding of lymphocytes to vascular endothelium in many tissues, including LNs, PPs, and multiple extranodal sites of inflammation (6, 8) . The endothelial ligands for LFA-1 include ICAM-1 and ICAM-2 (5).
Multistep model of lymphocyte/endothelial adhesion.
Studies on the adhesive interactions between leukocytes and vascular endothelium under flow or shear force reveal that such interactions involve a number of diverse CAMs in a multiple-step process ( Fig. 1) (4, 6, 17) . An initial transient Obviously, CAMs are not only involved in lymphocyte migration but also play critical roles in many other aspects of the immune response. However, in this article we will focus our discussion on the involvement of CAMs in lymphocyte migration into the pancreatic islets.
To investigate lymphocyte migration in a chronic inflammatory disease such as IDDM, a series of studies covering different time points during the disease process is necessary. For this purpose, animal models have been used to delineate the lymphocyte/endothelial adhesion pathways involved in the diabetogenic process. The NOD mouse offers an ideal model for these studies because 1) it spontaneously develops IDDM that closely resembles human IDDM; 2 ) it develops lymphocytic infiltrates in several wgans, including pancreas, thyroid, and salivary glands, allowing comparison of different tissue-selective adhesion pathways in the same animal; and 3 ) mAbs are available against a wide variety of murine lymphocyte and endothelial CAMs.
TISSUE-SELECTIVE LYMPHOCYTE MIGRATION TO PANCREATIC ISLETS IN IDDM: LESSONS FROM NOD MICE
The developmental biology of vascular CAM expression in NOD mouse pancreas has been investigated using immunohistochemistry. MAdCAM-1, but no PNAd, is found on many vessels in exocrine pancreas of both NOD and control C57BLKA mice during the first 3 weeks after birth. In NOD mice, T-cells and macrophages are first detected in the islets at -18-21 days of age. Macrophages (Mac-1') appear to enter the islets a few days earlier than CD3+ T-cells. Vessels with the morphology of high endothelial venules, which are the vessels involved in most lymphocyte migration from blood into LNs and PPs, develop aaacent to the islets at the time when T-cells enter the islets (X.-D.Y., S.A.M., R.E.M., I.W., H.O.M., unpublished observations). These observations suggest that monocytes or macrophages may be the initial islet-infiltrating cells and that the formation of high endothelial venules may be crucial for the early lymphocytic accu- cells, including T-and p-cells, accumulate around the islets @eri-insulitis) and gradually invade the islets (intra-insulitis). In parallel with the development of insulitis, expression of some CAMs is upregulated, while that of others remains unchanged (Table 2 ) (25,261.
MAdCAM-1 seems to be the predominant addressin expressed on ECs in and acijacent to the islets at early stages of insulitis (5-7 weeks). In contrast, very little PNAd expression is seen until there is significant insulitis (-8 weeks of age). As insulitis progresses, the number of vessels expressing MAdCAM-1 and PNAd increases ( Table 2 ). Both of these addressins are expressed mainly by peri-islet high endothelial venules (25) .
While few L-selectin expressing lymphocytes are found in the islets during the early stages of insulitis, most infiltrating cells express high levels of the a4p7 integrin throughout the disease process. The expression of a4p7 by lymphocytes correlates with high expression of MAdCAM-1 by ECs, further suggesting a predominant role for the mucosal lymphocyte homing pathway in the development of insulitis (25, 341 . Moreover, most islet-infiltrating T-cells express low levels of L-selectin and high levels of LFA-1, u4p7, VLA-4, and CD44, a phenotype for activatedlmemory T-cells (26) .
The tissue nonspecific CAMs, such as LFA-1 and ICAM-1, are expressed by almost all islet-infiltrating lymphocytes during the disease process. ICAM-1 is expressed by the endothelium of most islet vessels in both uninflamed and inflamed islets (25, 261 . It remains uncertain whether islet endocrine cells, particularly the p-cells, express ICAM-1. If ICAM-1 is expressed, an LFA-l/ICAM-1 interaction between lymphocytes and target p-cells could have at least two potential functions: 1) delivery of costimulatory signals for activation of T-cells andlor 2 ) mediation of direct killing of p-cells by cytotoxic T-cells. The failure to detect expression of ICAM-1 on islet endocrine cells may simply be due to the low sensitivity of current immunohistochemical approaches.
VCAM-1 is expressed by vessels in exocrine and endocrine pancreas of diabetes-prone NOD mice as well as nondiabetes-prone BALB/c mice (25, 26, 35) . Only a few VCAM-Iexpressing vessels are found within the islets (uninflamed or inflamed), whereas many are found in the exocrine-pancreas (Table 2 ). There is also VCAM-1 expression on some dendritic cells infiltrating the NOD islets (26) . These findings mulation.
From 3 weeks of age, increasing numbers of mononuclear suggest that these tissue nonspecific CAMs may function as costimulatory molecules in the local immune response. -, no effect; -I+, 0-500h inhibition of diabetes incidence; +, 50-60%
determined.
Alternatively, they may play accessory roles in mediating lymphocytic infiltration into the pancreas. In addition to inflammation of the pancreatic islets, NOD mice develop lymphocytic infiltration of other organs such as salivary gland and thyroid. This makes NOD mice an invaluable model to study the mechanisms involved in tissueselective lymphoc-yte trafficking to sites of chronic infiammation. In contrast to insulitis, which develops in the first few weeks of life, overt lymphocytic infiltration of the salivary gland (sialadenitis) is not seen in our colony until around 6 months of age. The inflamed salivary glands show marked vascular expression of PNAd and VCAM-1 but no detectable expression of MAdCAM-1 (26, 34) . ICAM-1 is expressed by ECs as well as dendritic cells in the infiltrated areas. The lymphocytes infiltrating the salivary glands show CAM expression similar to that of LN lymphocytes: LFA-I+, CD44+, some L-selectin+, and many a4+ (26) .
Overall, these findings suggest that an interaction of mucosal homing receptor a4@7 and its vascular addressin, MAdCAM-1, is a major adhesion pathway responsible for selective lymphocytic migration to the islets, while VL4-41 VCAM-1 and probably L-selectin1PNAd interactions may primarily mediate lymphocyte migration into salivary glands and possibly other organs (34) . More importantly, this type of tissue-selective homing in a chronic inflammatory disease appears to be determined by the selective expression of vascular addressins on ECs (34) .
In vivo studies using mAbs that recognize lymphocyte or EC CAMS have been carried out to determine which adhesion pathway or pathways have a prominent role during the diabetogenic process (Table 3) . Treatment of NOD mice with mAb Mel-14 (anti-L-selectin) leads to efficient protection against the spontaneous occurrence of IDDM if given early in the disease process, e.g., from birth to 4 weeks of age (34, 36) . However, Mel-14 is unable to inhibit an ongoing diabetogenic process if administered after the onset of insulitis, for instance at 10 weeks of age (34) . This may simply be due to the fact that most T-cells in young animals have a naive phenotype se select in^'^^), whereas more T-cells with an activatedmemory phenotype (L-selectin-Or 'Ow ) are found in older mice. Recently, it has been shown that only the L-selectin-T-cell population from diabetic NOD mice is able to transfer the disease (37) . These data imply that L-selectin may only play a role in the initial phase of insulitis development in young animals (<4 weeks) and that in the late phase, inhibition; + +, 60-80% inhibition; + + +, >80% inhibition; ND, not integrins such as a4@7 can function to mediate both lymphocyte rolling and strong adhesion on ECs in the mucosal lymphoid tissues (6, 7) . Strikingly, when the a4-integrin receptor is blocked by the Rl-2 mAb, NOD mice are signscantly protected from both spontaneous diabetes and adoptive-transfer disease (24, 34, 35, 38) . This treatment also prevents the development of insulitis, suggesting that protection from IDDM by R1-2 mAb may result from direct inhibition of lymphocyte migration into the islets (24, 34) . Moreover, our preliminary data demonstrate that antiLp7-integrin and anti-MAdCAM-1 mAbs can also inhibit spontaneous development of IDDM in NOD mice (Table 3) . Anti-VCAM-1 antibody marginally delays but fails to prevent disease in an adoptive-transfer model (35) . Unlike anti-LFA-1 and anti-ICAM-1 treatment, which induces tolerance (39) , blockade of L-selectin or a4-integrin receptor appears to affect neither autoimmune responses to @-cells nor immune responses to foreign antigens, suggesting that the IDDM-protective effect induced by blocking L-selectin or a4-integrin receptors is not a result of immune suppression (24, 34, 40) . Interestingly, the inhibition seems to be tissue-selective, because sialadenitis is unaffected by either anti-L-selectin or anti-a4integrin treatment (34) .
Blocking LFA-1 andlor ICAM-1 receptors in vivo by specific mAbs has been shown to inhibit the spontaneous development of IDDM in NOD mice and streptozotocin (STZ)-induced insulitis and diabetes in mice (Table 3 ) (41) (42) (43) . Nevertheless, it remains controversial whether the LFA-IACAM-1 lymphocytelendothelial adhesion pathway is involved in the diabetogenic process, since administration of both anti-LFA-1 and anti-ICAM-1 mAbs is required to prevent STZ-induced disease and treatment with either anti-LFA-1 or anti-ICAM-1 fails to inhibit disease in adoptive-transfer model in NOD mice (42, 43) . This raises the question of how LFA-1 and ICAM-1 function in the development of autoimmunity and diabetes. On one hand, it is conceivable that LFA-1ACAM-1 may be involved in strengthening the interaction between T-cells and target p-cells and facilitating p-cell killing andor provide costimulatory signals for T-cell activation (5) . On the other hand, there does not appear to be increased LFA-1 and ICAM-1 expression in inflamed islets during disease progression (Table 2) . Therefore, LF' A-MCAM-1 interactions may not be a s important as the a407hLAdCAM-1 pathway in the control of tissue-selective lymphocyte hom-ing to the islets. One potential problem in using anti-LFA-1 and anti-ICAM-1 treatment as a therapy is the risk of inducing immune suppression and/or exacerbation of the disease. Treatment of mice with anti-LFA-1 or anti-ICAM-1 enhances the severity of experimental allergic encephalomyelitis, an animal model for multiple sclerosis (44) .
Blocking ccMP2-integrin (Mac-1) with ahti-Mac-1 antibody also prevents dlabetes in an adoptive-transfer model in NOD mice, possibly via inhibiting recruitment of monocytes, macrophages, and other inflammatory cells in the islets (45) . During the evolution of diabetes, expression of certain CAMs such as MAdCAM-1 in the islets may be developmentally programmed and may have a crucial role in initial tissue-selective lymphocyte migration and in the priming of autoreactive lymphocytes. After activation, lymphocytes and inflammatory cells release a variety of biologically active materials, such as cytokines and chemokines, which in turn activate and stimulate expression of CAMs on ECs and lymphocytes, resulting in more lyrnphocytic influx (46, 47) . Among these cytokines, TNF-a, y-interferon, and interleukin-10, are known to be involved in stimulation of CAM expression and are essential for the formation of insulitis (48) (49) (50) (51) (52) (53) . Thus, expression of CAMs and their role in the diabetogenic process may in turn be regulated by cytokine production and function.
Lymphocyte-endothelial adhesion followed by transendothelial migration is a key event in the development of organspecific autoimmunity. Selective interactions of certain cellsurface molecules regulate lymphocyte migration under normal as well as pathological inflammatory conditions. NOD mice are an ideal model for investigation of the role of CAMs in regulation of lymphocyte migration t o the target organs in chronic inflammatory diseases such as IDDM. Both immunohistological and in vivo therapeutic studies in NOD mice strongly suggest that there are tissue-selective lymphocytic homing pathways for insulitis development; the mucosal (a4P7/MAdCAM-1) adhesion system appears to be one of the predominant ones. The fact that blocking these pathways leads to successful intervention in the diabetogenic process suggest that CAMs provide a potential therapeutic target for human IDDM (36, 61) . Further studies on IDDM patients will prove helpful for understanding IDDM pathogenesis, in addition to providing a basis for designing CAM-based therapeutic approaches. 
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THE ROLE OF CAMS IN HUMAN IDDM
The function of CAMs in human IDDM has recently been investigated. However, such studies are hampered by the limited availability of human pancreatic tissues, particularly from prediabetic individuals. Much of the published work has compared expression of certain CAMs in the pancreases of diabetlc or newly diagnosed diabetic patients with the pancreases from individuals without diabetes (54) (55) (56) (57) . By immunostaining, ICAM-1 has been found on the vessels of inflamed islets but not on vessels from uninflamed pancreases. It is still unclear whether ICAM-1 is expressed on endocrine cells found within the islets (54, 57, 58) . LFA-3, an EC ligand for CD2, is found on ECs of pancreases taken from people with IDDM. In two IDDM patients, VCAM-1 expression was found on some dendritic cells scattered throughout the pancreas but not on vascular endothelium (65, 57) .
The significance and implication of these results in human IDDM remains uncertain, especially with regard to the function of these molecules in the control of lymphocyte trafficking. Furthermore, since the majority of studies have used pancreatic material from overtly diabetic patients, the end stage of the diabetogenic process, it is difficult to assess the potential function of CAMs during the early development of insulitis.
One interesting aspect of such studies in humans is the observation that the serum levels of the extracellular domain of CAMs such as soluble ICAM-1 (SICAM-1) appear to be increased in some IDDM patients and their first-degree relatives (59, 60) . In addition, SICAM-1 appears to inhibit specific anti-p-cell T-cell responses (59) . Whether these observed phenomena are specific to the diabetogenic process and what role soluble CAMs may play in the autoimmune response anti diabetes process need further investigation.
